Pharmexa A/S Loses European Patent Appeal for Broad Claims to Telomerase-Based Cancer Vaccines

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that the Technical Board of Appeal of the European Patent Office (EPO) has affirmed the decision to revoke the claims of European Patent 1093381 as granted to Pharmexa in 2003. “We are pleased with the decision,” said David J. Earp, J.D., Ph.D., Geron’s chief patent counsel and senior vice president of business development. “It confirms that Pharmexa cannot obtain a patent to something already covered by Geron’s previously published patent application.”